Patients with elevated concentrations of blood fats, such as LDL (low-density lipoprotein), often suffer from severe vascular diseases that can lead to heart attacks, strokes and coronary heart disease.

If this lipid metabolism disorder is not adequately treatable through changes in dietary habits and medications, treatment using the so-called Lipid Apheresis is a viable option. During the therapy, lipoprotein(a), triglycerides, and LDL cholesterol are filtered out from the blood plasma, effectively reducing blood fats.

Numerous studies have demonstrated the effectiveness and safety of this treatment.

“It was concluded that lipoprotein apheresis is a safe and effective technique that could be considered in the management of hypercholesterolemia and future risk.”
Raina R, et al. Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. Blood Purif. 2019

“Lipoprotein apheresis (LA) could not only reduce LDL-C and Lp(a) in parallel, but also different inflammatory and coagulation parameters. In summary lipoprotein apheresis is not only anti-atherosclerotic, but also anti-inflammatory and anti-thrombotic and therefore an ideal treatment option with respect to the shown reduction of major adverse coronary events (MACE) and major adverse non-coronary events (MANCE) by reducing Lp(a) levels.”
Schettler, V.J.J., et al. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clin Res 2019